Results 171 to 180 of about 360,869 (356)
Correction: Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. [PDF]
Lee J +6 more
europepmc +1 more source
SPARK is an interactive platform hosting 189,232 human testicular single‐cell transcriptomes across normal and infertile conditions. It enables automated, code‐free analysis and visualization, providing a powerful resource to explore cellular and molecular dynamics in male reproduction and infertility.
Lina Cui +9 more
wiley +1 more source
Steerable versus Conventional flexible and navigable suction ureteral access sheath (FANS) flexible Ureteroscopy for Lower Pole stones Treatment: study protocol for a multicentre, randomised superiority trial (SCULPT trial). [PDF]
Yuen SKK +30 more
europepmc +1 more source
This review explores the role of metabolic reprogramming in inflammatory bowel disease (IBD) by focusing on immune and epithelial cell metabolism, microbial metabolites, and their impact on inflammation. It discusses emerging metabolic therapies and emphasizes the importance of personalized microbiota‐targeted approaches to improve clinical outcomes in
Zemin Tian +6 more
wiley +1 more source
Bladder masses simulating neoplasia in chronic granulomatous disease: Diagnostic challenges and spontaneous regression. [PDF]
Dadpour M +3 more
europepmc +1 more source
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol +5 more
wiley +1 more source

